• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Surmodics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/8/25 7:00:09 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care
    Get the next $SRDX alert in real time by email
    8-K
    0000924717false00009247172025-08-082025-08-08

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 08, 2025

     

     

    Surmodics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Minnesota

    0-23837

    41-1356149

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    9924 West 74th Street

     

    Eden Prairie, Minnesota

     

    55344

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 952 500-7000

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.05 par value

     

    SRDX

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On August 8, 2025, Surmodics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of the full text of the Press Release is furnished as Exhibit 99.1 to this report.

    The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit

    Number

     

     

    Description

    99.1

     

    Press Release dated August 8, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    SURMODICS, INC.

     

     

     

     

    Date:

    August 8, 2025

    By:

    /s/ Timothy J. Arens

     

     

     

    Timothy J. Arens
    Senior Vice President of Finance and Chief Financial Officer

     


    Get the next $SRDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRDX

    DatePrice TargetRatingAnalyst
    3/7/2025$43.00Hold → Buy
    Lake Street
    6/13/2023$36.00Hold → Buy
    Needham
    2/13/2023Buy → Hold
    Needham
    2/4/2022$70.00 → $58.00Buy
    Needham
    11/10/2021$76.00 → $70.00Buy
    Needham
    9/8/2021$68.00 → $76.00Buy
    Needham
    More analyst ratings

    $SRDX
    SEC Filings

    View All

    SEC Form 10-Q filed by Surmodics Inc.

    10-Q - SURMODICS INC (0000924717) (Filer)

    8/8/25 7:55:24 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SURMODICS INC (0000924717) (Filer)

    8/8/25 7:00:09 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Surmodics Inc.

    SCHEDULE 13G - SURMODICS INC (0000924717) (Subject)

    7/15/25 11:55:22 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heine Lisa Wipperman covered exercise/tax liability with 2,115 shares and exercised 2,640 shares at a strike of $27.30, increasing direct ownership by 4% to 13,978 units (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    2/20/25 4:12:56 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Director Dantzker David exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,216 shares, increasing direct ownership by 3% to 40,183 units (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    2/18/25 5:22:54 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Director Bedoya Jose H exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,224 shares, increasing direct ownership by 4% to 30,008 units (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    2/18/25 5:20:51 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Financials

    Live finance-specific insights

    View All

    Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $29.6 million, an increase of 1% year-over-year GAAP loss of $(5.3) million, compared to $(7.6) million in the prior-year period Adjusted EBITDA(2) of $3.4 million, compared to $1.6 million in the pr

    8/8/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be released before the market opens on Friday, August 8. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the third quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also

    8/6/25 4:05:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

    4/30/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    11/14/24 3:36:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    11/6/24 1:30:21 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    10/23/24 10:43:41 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Surmodics upgraded by Lake Street with a new price target

    Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00

    3/7/25 8:21:43 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics upgraded by Needham with a new price target

    Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00

    6/13/23 7:48:05 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics downgraded by Needham

    Needham downgraded Surmodics from Buy to Hold

    2/13/23 7:24:21 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $29.6 million, an increase of 1% year-over-year GAAP loss of $(5.3) million, compared to $(7.6) million in the prior-year period Adjusted EBITDA(2) of $3.4 million, compared to $1.6 million in the pr

    8/8/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be released before the market opens on Friday, August 8. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the third quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also

    8/6/25 4:05:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

    4/30/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Leadership Updates

    Live Leadership Updates

    View All

    KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting

    6/27/23 7:05:00 AM ET
    $KRMD
    $SRDX
    Medical/Dental Instruments
    Health Care